Post-transplant Lymphoproliferative Disorder
📧 Sign up to get email alerts when something new happens for Post-transplant Lymphoproliferative Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2017-03-22Clinical Trial Update: Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) [Phase 2]
A Phase 2 trial evaluating single-agent obinutuzumab for relapsed/refractory Post-transplant Lymphoproliferative Disorder has been withdrawn…